Somatostatin and gastrointestinal tract. Clinical experiences;A szomatosztatin és az emésztorendszer. Klinikai tapasztalatok

Orvosi Hetilap

Volumn 154, Issue 39, 2013, Pages 1535-1540

  Herszényi, László ^a   Mihály, Emese ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

gastrointestinal diseases; octreotid; oesophageal variceal bleeding; somatostatin

Indexed keywords

SOMATOSTATIN DERIVATIVE;

ADJUVANT THERAPY; ARTICLE; DRUG EFFICACY; ESOPHAGUS VARICES BLEEDING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; HUMAN; NEUROENDOCRINE TUMOR; PANCREAS FISTULA; WORK EXPERIENCE;

DIGESTIVE SYSTEM; DIGESTIVE SYSTEM DISEASES; DUMPING SYNDROME; ESOPHAGEAL AND GASTRIC VARICES; HUMANS; OCTREOTIDE; PANCREATIC DISEASES; PANCREATIC FISTULA; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 84885053282     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2013.29721     Document Type: Article

References (49)

1. Brazeau, P., Vale, W., Burgus, R., et al.: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science, 1973, 179, 77-79.
2. Burgus, R., Ling, N., Butcher, M., et al.: Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone. Proc. Natl. Acad. Sci. USA, 1973, 70, 684-688.
3. Pradayrol, J., Chayvialle, J. A., Carlguist, M., et al.: Isolation of a porcine intestinal peptide with C-terminal somatostatin. Biochem. Biophys. Res. Commun., 1978, 85, 701-708. (Pubitemid 9085901)
4. Polak, J. M., Pearse, A. G., Grimelius, L., et al.: Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet, 1975, 1 (7918), 1220-1222.
5. Van Op den Bosch, J., Adriaensen, D., Van Nassauw, L., et al.: The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review. Regul. Pept., 2009, 156, 1-8.
6. Corleto, V. D., Severi, C., Romano, G., et al.: Somatostatin receptor subtypes mediate contractility on human colonic smooth muscle cells. Neurogastroenterol. Motil., 2006, 18, 217-225.
7. Samson, W. K., Zhang, J. V., Avsian-Kretchmer, O., et al.: Neuronostatin encoded by the somatostatin gene regulates neuronal, cardiovascular and metabolic functions. J. Biol. Chem., 2008, 283, 31949-31959.
8. Gong, A. Y., Tietz, P. S., Muff, M. A., et al.: Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am. J. Physiol. Cell Physiol., 2003, 284, C1205-C1214. (Pubitemid 36457401)
9. Lang, A., Sakhnini, E., Fidder, H. H., et al.: Somatostatin inhibits pro-inflammatory cytokine secretion from rat hepatic stellate cells. Liver Int., 2005, 25, 808-816. (Pubitemid 41038662)
10. Gunshefski, L. A., Rifley, W. J., Slattery, D. W., et al.: Somatostatin stimulation of the normal esophagus. Am. J. Surg., 1992, 163, 59-62.
11. Kravetz, D., Bosch, J., Terés, J., et al.: Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal haemorrhage. Hepatology, 1984, 4, 442-446. (Pubitemid 14116645)
12. Walker, S., Stiehl, A., Raedsch, R., et al.: Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology, 1986, 6, 112-115. (Pubitemid 16137853)
13. Lo, G. H., Perng, D. S., Chang, C. Y., et al.: Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding. J. Gastroenterol. Hepatol., 2013, 28, 684-689.
14. Planas, R., Quer, J. C., Boix, J., et al.: A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding. Hepatology, 1994, 20, 370-375. (Pubitemid 24233363)
15. Avgerinos, A., Armonis, A., Raptis, S.: Somatostatin or octreotide versus endoscopic sclerotherapy in acute variceal haemorrhage: a meta-analysis study. J. Hepatol., 1995, 22, 247-248.
16. Jenkins, S. A., Kingsnorth, A. N., Ellenbogen, S., et al.: Octreotide in the control of post-sclerotherapy bleeding from oesophageal varices, ulcers and oesophagitis. HPB Surgery, 1996, 10, 1-6. (Pubitemid 26361447)
17. Jenkins, S. A., Shields, R., Davies, M., et al.: A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut, 1997, 41, 526-533. (Pubitemid 27448787)
18. D'Amico, G., Pietrosi, G., Tarantino, I., et al.: Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology, 2003, 124, 1277-1291. (Pubitemid 36531803)
19. Choi, C. W., Kang, D. H., Kim, H. W., et al.: Somatostatin adjunctive therapy for non-variceal upper gastrointestinal rebleeding after endoscopic therapy. World J. Gastroenterol., 2011, 17, 3441-3447.
20. Brown, C., Subramanian, V., Wilcox, C. M., et al.: Somatostatin analogues in the treatment of recurrent bleeding from gastrointestinal vascular malformations: an overview and systematic review of prospective observational studies. Dig. Dis. Sci., 2010, 55, 2129-2134.
21. Bassi, C., Dervenis, C., Butturini, G., et al., for the International Study Group on Pancreatic Fistula Definition: Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery, 2005, 138, 8-13. (Pubitemid 40933766)
22. Li-Ling, J., Irving, M.: Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br. J. Surg., 2001, 88, 190-199. (Pubitemid 32142703)
23. Bassi, C., Butturini, G., Molinari, F., et al.: Pancreatic fistula rate after pancreatic resection. The importance of definitions. Dig. Surg., 2004, 21, 54-59. (Pubitemid 38490179)
24. Tulassay, Z., Flautner, L., Vadász, A., et al.: Short report: octreotide in the treatment of external pancreatic fistulas. Aliment. Pharmacol. Ther., 1993, 7, 323-325. (Pubitemid 23198308)
25. Tulassay, Z., Flautner, L., Fehérvári, I., et al.: Somatostatin in the prevention of postoperative increase of pancreatic enzyme after pancreatic surgery. [Somatostatin a hasnyálmirigy-mtétek után kialakuló pancreas-enzim emelkedés megelzésében.] Orv. Hetil., 1992, 133, 777-780. [Hungarian]
26. Leandros, E., Antonakis, P. T., Albanopoulos, K., et al.: Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas. Can. J. Gastroenterol., 2004, 18, 303-306. (Pubitemid 38801784)
27. Gayral, F., Campion, J. P., Regimbeau, J. M., et al.: Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. Ann. Surg., 2009, 250, 872-877.
28. Zeng, Q., Zhang, Q., Han, S., et al.: Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas, 2008, 36, 18-25.
29. Ramos-De la Medina, A., Sarr, M. G.: Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. J. Hepatobiliary Pancreat. Surg., 2006, 13, 190-193.
30. Alghamdi, A. A., Jawas, A. M., Hart, R. S.: Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. Can. J. Surg., 2007, 50, 459-466.
31. Koti, R. S., Gurusamy, K. S., Fusai, G., et al.: Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB, 2010, 12, 155-165.
32. Coughlin, S., Roth, L., Lurati, G., et al.: Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis. World J. Surg., 2012, 36, 1016-1029.
33. Gans, S. L., van Westreenen, H. L., Kiewiet, J. J. S., et al.: Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. Br. J. Surg., 2012, 99, 754-760.
34. Tack, J., Arts, J., Caenepeel, P., et al.: Pathophysiology, diagnosis and management of postoperative dumping syndrome. Nat. Rev. Gastroenterol. Hepatol., 2009, 6, 583-590.
35. Tulassay, Z., Tulassay, T., Gupta, R., et al.: Long acting somatostatin analogue in dumping syndrome. Br. J. Surg., 1989, 76, 1294-1295. (Pubitemid 20026711)
36. Didden, P., Penning, C., Masclee, A. A.: Octreotide therapy in dumping syndrome: analysis of long-term results. Aliment. Pharmacol. Ther., 2006, 24, 1367-1375. (Pubitemid 44571567)
37. Arts, J., Caenepeel, P., Bisschops, R., et al.: Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping. Clin. Gastroenterol. Hepatol., 2009, 7, 432-437.
38. Perry, M. D., Sandle, G. I.: Regulation of colonic apical potassium (BK) channels by cAMP and somatostatin. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 297, G159-G167.
39. Abbas, Z., Moid, I., Khan, A. H., et al.: Efficacy of octreotide in diarrhoea due to Vibrio cholera: a randomized, controlled trial. Ann. Trop. Med. Parasitol., 1996, 90, 507-513. (Pubitemid 26345679)
40. Chatterjee, S., De Man, J., Van Marck, E.: Somatostatin and intestinal schistosomiasis: therapeutic and neuropathological implications in host-parasite interactions. Trop. Med. Int. Health, 2001, 6, 1008-1015. (Pubitemid 34008768)
41. Pai, V., Porter, K., Ranalli, M.: Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease. Pediatr. Blood Cancer, 2001, 56, 45-49.
42. Soudah, H. C., Hasler, W. L., Owyang, C.: Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N. Engl. J. Med., 1991, 325, 1461-1467.
43. Kobayashi, T., Kobayashi, M., Naka, M., et al.: Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis. Intern. Med., 1993, 32, 607-609. (Pubitemid 23360738)
44. Tulassay, Z., Kisfalvi, K., Papp, M.: The effect of the long-acting somatostatin analogue octreotide on caerulein-induced pancreatic injuries in rats. Z. Gastroenterol., 1995, 33, 99-102.
45. Tulassay, Z., Flautner, L., Sándor, Z., et al.: Perioperative use of somatostatin in pancreatic surgery. Acta Biomed. Ateneo Parmense, 1993, 64, 205-211.
46. Tulassay, Z., Döbrönte, Z., Prónai, L., et al.: Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment. Pharmacol. Ther., 1998, 12, 1109-1112. (Pubitemid 28508724)
47. Li, Z. S., Pan, X., Zhang, W. J., et al.: Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: a multicenter, placebo-controlled, randomized clinical trial. Am. J. Gastroenterol., 2007, 102, 46-51. (Pubitemid 46072042)
48. Herszényi, L., Tulassay, Z.: Octreotide in the prevention of post-ERCP pancreatic injury. Am. J. Gastroenterol., 2007, 102, 1539-1540. (Pubitemid 46976306)
49. Omata, F., Deshpande, G., Tokuda, Y., et al.: Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J. Gastroenterol., 2010, 45, 885-895.